Skip to content

Released Mar 30, 2021, before the open

10-K filed Mar 30, 2021, 89 days after period end · 0001558370-21-003681

Q4 2020 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$19.50Mderived+9.8% vs Q4 2019+80.7% vs Q3 2020
Net Income$397.00Kderived+36.4% vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$2,839,000+29.0%
Operating Cash Flowderived-$7,550,000N/M
Free Cash Flowderived-$7,825,000N/M
Margins · derived
Operating margin14.6%+2.2 pt vs Q4 2019
Net margin2.0%+0.4 pt vs Q4 2019

What the release said

The release

Same quarter

MetricQ4 2020derived from reported figuresQ4 2019Q4 2018Q4 2017derived from reported figures
Revenue$19.50M$17.76M$27.02M$4.31M
Net Income$397.00K$291.00K-$5.43M-$13.31M
EPS Diluted—$0.02-$0.40—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR